Allelic Loss at 1p34-36 Predicts Poor Prognosis in Node-negative Breast Cancer

• Utada Yoshihito

  Department of Gerontology, Nippon Medical School Department of Surgery and Pathology, Cancer Institute Department of Surgery, Daini Hospital, Tokyo Women's Medical University

• Emi Mitsuru

  Department of Gerontology, Nippon Medical School Department of Molecular Biology, Institute of Gerontology, Nippon Medical School

• Yoshimoto Masataka

  Department of Surgery and Pathology, Cancer Institute

• Kasumi Fujio

  Department of Surgery and Pathology, Cancer Institute

• Akiyama Futoshi

  Department of Surgery and Pathology, Cancer Institute

• Sakamoto Goi

  Department of Surgery and Pathology, Cancer Institute

• Haga Shunsuke

  Department of Surgery, Daini Hospital, Tokyo Women's Medical University

• Kajiwara Tetsuro

  Department of Surgery, Daini Hospital, Tokyo Women's Medical University

• Nakamura Yusuke

  Laboratory of Molecular Medicine, Institute of Medical Science, University of Tokyo

抄録

Allelic losses of specific chromosomal regions in the DNA of tumor cells, which imply loss of tumor suppressor genes normally resident at those loci, may become useful postoperative prognostic indicators for breast cancers that have not yet metastasized to lymph nodes. To examine whether specific allelic losses might correlate with postoperative disease-free survival, we tested tumors from a cohort of 228 node-negative breast cancer patients for allelic losses at 18 microsatellite loci chosen to represent either a known tumor suppressor gene or a region where genetic alterations are frequent in breast tumors. We followed the patients clinically for 5 years or until death (if patient death occurred before completion of 5 years of follow-up). Patients whose tumors had lost an allele at 1p34-36 bore significantly higher risks of postoperative recurrence than those whose tumors retained both alleles of the markers in that region [the 5-year recurrence rate was 15% among patients with losses versus 2% among patients with retention (P=0.001)]. Multivariate analysis demonstrated that allelic loss at 1p34-36 was an independent postoperative predictor of shorter disease-free survival (hazard ratio, 5.8; P=0.0117). Thus, allelic losses at 1p34-36 in a tumor might have a potential to serve as a negative prognostic indicator to guide postoperative management of breast cancer patients, especially in the selection of high-risk women who will benefit from adjuvant chemotherapy and endocrine therapy.

収録刊行物

• 日本医科大学老人病研究所紀要

  日本医科大学老人病研究所紀要 7 89-94, 2001-03-25

  日本医科大学

詳細情報

• CRID: 1573387451667398272
• NII論文ID: 110001071250
• NII書誌ID: AN1047681X
• ISSN: 13409662
• 本文言語コード: en
• データソース種別:
  • CiNii Articles